236 related articles for article (PubMed ID: 29501590)
1. Modeling of pharmacokinetics, efficacy, and hemodynamic effects of macitentan in patients with pulmonary arterial hypertension.
Krause A; Zisowsky J; Dingemanse J
Pulm Pharmacol Ther; 2018 Apr; 49():140-146. PubMed ID: 29501590
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects.
Issac M; Dingemanse J; Sidharta PN
J Clin Pharmacol; 2017 Aug; 57(8):997-1004. PubMed ID: 28378883
[TBL] [Abstract][Full Text] [Related]
3. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Macitentan in Patients With Eisenmenger Syndrome.
Gatzoulis MA; Landzberg M; Beghetti M; Berger RM; Efficace M; Gesang S; He J; Papadakis K; Pulido T; Galiè N;
Circulation; 2019 Jan; 139(1):51-63. PubMed ID: 30586694
[TBL] [Abstract][Full Text] [Related]
6. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
[TBL] [Abstract][Full Text] [Related]
7. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
Mehta S; Sastry BKS; Souza R; Torbicki A; Ghofrani HA; Channick RN; Delcroix M; Pulido T; Simonneau G; Wlodarczyk J; Rubin LJ; Jansa P; Hunsche E; Galiè N; Perchenet L; Sitbon O
Chest; 2017 Jan; 151(1):106-118. PubMed ID: 27671974
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
[TBL] [Abstract][Full Text] [Related]
9. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
Jansa P; Pulido T
Am J Cardiovasc Drugs; 2018 Feb; 18(1):1-11. PubMed ID: 29280064
[TBL] [Abstract][Full Text] [Related]
10. Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
Channick RN; Delcroix M; Ghofrani HA; Hunsche E; Jansa P; Le Brun FO; Mehta S; Pulido T; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A; Galiè N
JACC Heart Fail; 2015 Jan; 3(1):1-8. PubMed ID: 25457902
[TBL] [Abstract][Full Text] [Related]
11. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
Ghofrani HA; Simonneau G; D'Armini AM; Fedullo P; Howard LS; Jaïs X; Jenkins DP; Jing ZC; Madani MM; Martin N; Mayer E; Papadakis K; Richard D; Kim NH;
Lancet Respir Med; 2017 Oct; 5(10):785-794. PubMed ID: 28919201
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension.
Souza R; Delcroix M; Galié N; Jansa P; Mehta S; Pulido T; Rubin L; Sastry BKS; Simonneau G; Sitbon O; Torbicki A; Boyanova N; Chamitava L; Stein C; Channick RN
Adv Ther; 2022 Sep; 39(9):4374-4390. PubMed ID: 35819570
[TBL] [Abstract][Full Text] [Related]
13. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results.
Aypar E; Alehan D; Karagöz T; Aykan H; Ertugrul İ
Cardiol Young; 2020 May; 30(5):681-685. PubMed ID: 32290885
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension.
Monaco TJ; Davila CD
Drug Des Devel Ther; 2016; 10():1675-82. PubMed ID: 27274200
[TBL] [Abstract][Full Text] [Related]
16. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.
Tahara N; Dobashi H; Fukuda K; Funauchi M; Hatano M; Ikeda S; Joho S; Kihara Y; Kimura T; Kondo T; Matsushita M; Minamino T; Nakanishi N; Ozaki Y; Saji T; Sakai S; Tanabe N; Watanabe H; Yamada H; Yoshioka K; Sasayama S
Circ J; 2016 May; 80(6):1478-83. PubMed ID: 27180890
[TBL] [Abstract][Full Text] [Related]
18. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease.
Herbert S; Gin-Sing W; Howard L; Tulloh RMR
Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536
[TBL] [Abstract][Full Text] [Related]
19. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-pharmacodynamic relationships of macitentan, a new endothelin receptor antagonist, after multiple dosing in healthy Korean subjects.
Ahn LY; Kim SE; Yi S; Dingemanse J; Lim KS; Jang IJ; Yu KS
Am J Cardiovasc Drugs; 2014 Oct; 14(5):377-85. PubMed ID: 24906252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
